Tetrabamate ( Atrium, G Tril, Sevrium) is a combination drug formulation of febarbamate, difebarbamate, and phenobarbital which was marketed in France and Spain and was used to treat anxiety and alcohol withdrawal-associated muscle tremors, agitation, and depression. [1 ] [2 ] [3 ] It was largely, but not completely [4 ] discontinued on April 4, 1997 after over 30 years of use due to reports of hepatitis and acute liver failure. [3 ] [4 ] [5 ] The decision to restrict the use of the drug had been long-awaited. [6 ] [6 ]
References [ edit ]
^ . Taylor & Francis US. 2000. pp. 333 & 427. Index nominum 2000: international drug directory ISBN 978-3-88763-075-1 . Retrieved 26 November 2011.
^ Eugene R. Schiff; Willis C. Maddrey; Michael F. Sorrell (19 October 2011). . John Wiley and Sons. p. 2276. Schiff's Diseases of the Liver ISBN 978-1-119-95048-6 . Retrieved 26 November 2011.
^ a b Binder D, Jost R, Flury R, Salomon F (May 1995). "[Acute liver failure following tetrabamate]". Schweizerische Medizinische Wochenschrift (in German) 125 (19): 965–9. PMID 7761807.
^ a b . United Nations Publications. 2003. p. 259. Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments ISBN 978-92-1-130230-1 . Retrieved 26 November 2011.
^ Horsmans Y, Lannes D, Pessayre D, Larrey D (December 1994). "Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate". Journal of Hepatology 21 (6): 1075–9. PMID 7699230.
^ a b "Severe hepatitis due to Atrium". Prescrire International 10 (55): 150. October 2001. PMID 11824432.